Cancer News: Sarcoma
The FDA granted approval to olaratumab with doxorubicin combination treatment for patients with advanced soft tissue sarcoma (STS).
The existing cancer immunotherapy pembrolizumab induced positive outcomes to patients with undifferentiated pleomorphic sarcoma.
Pulmonary metastasectomy was associated to prolonged survival in patients with metastatic soft tissue sarcoma, a new data analysis shows.
EU regulators have approved eribulin for the treatment of adult patients with unresectable liposarcomas.
Older patients with soft tissue sarcomas responded better to radiation therapy following surgery compared to their younger counterparts, a new study reveals.
Eisai’s breast cancer drug eribulin mesylate (Halaven) received FDA’s approval to treat patients with liposarcoma.
U.S regulators approved trabectedin (Yondelis) for the treatment of certain types of unresectable or metastatic soft-tissue sarcomas.
Trabectedin (Yondelis) reduced the risk of disease progression in the largest randomized Phase 3 study ever conducted in patients advanced soft tissue sarcoma.
A large study of Yondelis in soft-tissue sarcoma patients confirms the drug is effective in delaying progression, even more than in clinical trials.
An analysis has confirmed the importance of known prognostic factors for the long-term outcome in treatment with pazopanib for metastatic soft tissue sarcoma.
A small clinical trial has tested new treatment combination against resistant sarcomas. The results show that the growth of these tumors can be stabilized.